Phase I Epilepsy Vaccine Trial
100% of patients randomized on time.
Flourish Research has the infrastructure and expertise to help sponsors rapidly enroll vaccine studies while maintaining high-quality delivery.
Talk to our experts about how we can advance your trial.
|
|
|
100% of patients randomized on time.
Randomized 340+ patients, achieving 165% of enrollment target within the study timeline.
Achieved 198% of enrollment target on schedule.
Peripheral blood mononuclear cells (PBMC) capabilities are critical in assessing immune responses in vaccine clinical trials.
Flourish Research offers in-house PBMC labs to for greater efficiency across our network.
Principal Investigator and VP of Physician Engagement, Flourish Research – Chicago
Principal Investigator, Flourish Research – Walnut Creek
Connect with our team to see how quickly we can begin recruiting for your study.
Stay current with the latest clinical trial news and learn how Flourish Research is supporting the advancement of life-changing therapeutics.